# Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

> **NCT06814548** · — · NOT_YET_RECRUITING · sponsor: **Yongxu Jia** · enrollment: 200 (estimated)

## Conditions studied

- Gastric Cancer, Gastroesophageal Junction Cancer
- Immune Checkpoint Inhibitors (ICIs)
- Second-line
- Retreatment

## Interventions

- **OTHER:** ICIs(Immune checkpoint inhibitors)

## Key facts

- **NCT ID:** NCT06814548
- **Lead sponsor:** Yongxu Jia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814548, "Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06814548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*